VivoSeq
Neurology

Familial Amyotrophic Lateral Sclerosis

4

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Familial Amyotrophic Lateral Sclerosis is an early-stage landscape with 4 programs across 1 company. The most active players are Ionis Pharmaceuticals. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ionis Pharmaceuticals logo

Ionis Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed4 · 100%

Clinical Trials

Trial Activity

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 1·NCT01041222·33 enrolled
F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis
Completed·TTammie L. S. Benzinger, MD, PhD·N/A·NCT02414230·9 enrolled
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)
Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT01083667·32 enrolled
Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
Completed·UUniversity of Miami·Phase 2/3·NCT00706147·38 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)